Serum Amyloid A: a Biomarker for Renal Cancer
Anticancer Research,  Clinical Article

Fischer K et al. – The results indicate that advanced renal cancers are accompanied by increased levels of acute–phase proteins such as C–reactive protein (CRP) and SAA. Serum amyloid A (SAA) is found to be more sensitive than CRP for the indication of advanced renal cancer.

Methods
  • In thestudy, 48 patients with localized and 67 patients with advanced renal tumors were included.
  • 24 patients served as a control group.
  • Interleukine 6 (IL-6), C-reactive protein (CRP) and SAA levels were measured preoperatively and at day 5 after nephrectomy.

Results
  • The IL-6, CRP and SAA levels in patients with advanced tumors are significantly higher than those of patients with localized tumors.
  • Advanced tumors were identified with a sensitivity of 78% (SAA), 69% (CRP) and 44% (IL-6).
  • The specificity was 82%, 82% and 94% for SAA, CRP and IL-6, respectively.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

    Currently, there are no available articles.

Your Unread Messages in Nephrology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Nephrology Articles

Indexed Journals in Nephrology: Kidney International, Hemodialysis International, Nephrology Dialysis Transplantationmore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close